Drug Landscape ›
Simvastatin 80mg ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 38
Most-reported reactions
Rhabdomyolysis — 9 reports (23.68%) Acute Kidney Injury — 6 reports (15.79%) Myalgia — 6 reports (15.79%) Drug Interaction — 3 reports (7.89%) Myopathy — 3 reports (7.89%) Pain In Extremity — 3 reports (7.89%) Asthenia — 2 reports (5.26%) Blood Creatine Phosphokinase Increased — 2 reports (5.26%) Fatigue — 2 reports (5.26%) Hypercalcaemia — 2 reports (5.26%)
Source database →
Simvastatin 80mg in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Simvastatin 80mg approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Simvastatin 80mg in United States?
Helsinki University Central Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.